Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.820
+0.320 (7.11%)
At close: Aug 22, 2025, 4:00 PM
4.890
+0.070 (1.45%)
After-hours: Aug 22, 2025, 6:07 PM EDT

Monte Rosa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
Net Income
24.17-72.7-135.35-108.5-73.96-35.88
Upgrade
Depreciation & Amortization
10.6210.228.323.752.130.54
Upgrade
Loss (Gain) From Sale of Assets
-0.06--0.02-0.110.02-
Upgrade
Loss (Gain) From Sale of Investments
-3.55-2.95-3.78-1.95--
Upgrade
Stock-Based Compensation
18.9418.1316.6711.665.20.35
Upgrade
Other Operating Activities
-2.28-2.1-2.14.810.967.68
Upgrade
Change in Accounts Receivable
9.330.331.9-0.19--
Upgrade
Change in Accounts Payable
-1.056.255.76-0.74-0.713.44
Upgrade
Change in Unearned Revenue
-26.7783.3850---
Upgrade
Change in Other Net Operating Assets
-1.631.4414.81-1.26.990.82
Upgrade
Operating Cash Flow
27.7242-43.8-92.47-59.36-23.05
Upgrade
Capital Expenditures
-3.86-3.99-19.04-12.91-9.73-3.39
Upgrade
Sale of Property, Plant & Equipment
--0.060.110.08-
Upgrade
Investment in Securities
-64.19-40.46107.78-206.42--
Upgrade
Investing Cash Flow
-68.05-44.4588.8-219.22-9.65-3.39
Upgrade
Issuance of Common Stock
152.532.6121.45255.79-
Upgrade
Other Financing Activities
-46.3624.88-0.98-21.23-0.44
Upgrade
Financing Cash Flow
198.8927.4920.47377.5660.06
Upgrade
Net Cash Flow
-39.3396.4472.49-291.22308.5533.62
Upgrade
Free Cash Flow
23.8538.01-62.84-105.38-69.1-26.44
Upgrade
Free Cash Flow Margin
13.40%50.26%----
Upgrade
Free Cash Flow Per Share
0.290.51-1.22-2.23-2.76-17.43
Upgrade
Levered Free Cash Flow
40.7581.97-53.37-72.4-61.297.6
Upgrade
Unlevered Free Cash Flow
40.7581.97-53.37-72.4-61.297.6
Upgrade
Change in Working Capital
-20.1291.472.47-2.136.294.26
Upgrade
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q